Psychotropic side effects of commonly prescribed medications in the elderly

Primary Psychiatry

Volumn 11, Issue 8, 2004, Pages 27-34

  Desai, Abhilash K ^a,b  

^a S Louis Univ Sch Med/Cardinal G   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; DEXTROMETHORPHAN; DIGOXIN; DIPHENHYDRAMINE; DIURETIC AGENT; FLURAZEPAM; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; LITHIUM; LORAZEPAM; MESORIDAZINE; NEUROLEPTIC AGENT; NON PRESCRIPTION DRUG; OXAZEPAM; PSYCHOTROPIC AGENT; RANITIDINE; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; THIORIDAZINE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADVERSE DRUG REACTION; AGED; AKATHISIA; ANXIETY DISORDER; APATHY; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; CONCENTRATION LOSS; CONFUSION; DECREASED ALERTNESS; DELIRIUM; DEMENTIA; DEPRESSION; DISEASE EXACERBATION; DOSE RESPONSE; DREAMING; DRUG EFFECT; DRUG INDUCED DISEASE; EVALUATION; FATIGUE; GERIATRIC CARE; HALLUCINATION; HEART PALPITATION; HIGH RISK POPULATION; HUMAN; HYPERPYREXIA; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; LIVER FAILURE; MEMORY DISORDER; MENTAL DISEASE; MOOD DISORDER; MORBIDITY; MORTALITY; NERVOUSNESS; PARANOIA; PARESTHESIA; POLYPHARMACY; PRIMARY PREVENTION; PSYCHOMOTOR DISORDER; PSYCHOSIS; PSYCHOTROPIC SIDE EFFECT; REVIEW; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SKIN TINGLING; SLEEP DISORDER; SOMNOLENCE; SUBSYNDROMAL PSYCHOTROPIC SIDE EFFECT; SYMPTOM; TREMOR; VISUAL HALLUCINATION; WEIGHT GAIN;

EID: 4344636253     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older out-patients. J Am Geriatr Soc. 1997;45(8):945-948.
2. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107-1116.
3. Avorn J, Gurwitz JH. Principles of pharmacology. In: Cassel CK, Cohen HJ, Larson EB, et al. Geriatric Medicine. New York, NY: Springer-Verlag; 1997:55-70.
4. Nolan L, O'Malley K. Prescribing for the elderly. Part I: Sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc. 1988;36(2):142-149.
5. Flaherty JH. Commonly prescribed and over-the-counter medications: causes of confusion. Clin Geriatr Med. 1998;14(1):101-127.
6. Physicians' Desk Reference. 58th ed. Montvale, NJ: Thompson PDR; 2004.
7. Drug Facts and Comparisons. 58th ed. St. Louis, MO: Wolters Kluwer Health, Inc.; 2004.
8. Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf. 1999;21(2):101-122.
9. Inouye SK. The dilemma of delirium: clinical and research controversies regarding diagnosis and evaluation of delirium in hospitalized elderly medical patients. Am J Med. 1994;97(3):278-288.
10. Starr JM, Whalley LJ. Drug-induced dementia. Incidence, management and prevention. Drug Saf. 1994;11(5):310-317.
11. Larson EB, Reifler BV, Sumi SM, Canfield CG, Chinn NM. Diagnostic evaluation of 200 elderly outpatients with suspected dementia. J Gerontol. 1985;40(5)536-543.
12. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716-2724. Erratum in: Arch Intern Med. 2004;164(3):298.
13. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716-2724. Erratum in: Arch Intern Med. 2004;164(3):298.
14. Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. JAMA. 1996;275(11):852-857.
15. McCusker J, Cole M, Dendukuri N, Belzile E, Primeau F. Delirium in older medical inpatients and subsequent cognitive and functional status: a prospective study. CMAJ. 2001;165(5):575-583.
16. Chan D, Brennan NJ. Delirium: making the diagnosis, improving the prognosis. Geriatrics. 1999;54(3):28-42.
17. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15-28.
18. Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(suppl 21):11-14.
19. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287(3):337-344.
20. Cantu TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med. 1991;114(12):1027-1034.
21. Morgan T, Robson KM. Irritable bowel syndrome. Diagnosis is based on clinical criteria. Postgrad Med. 2002;112(5):30-41.
22. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ. 1997;156(3):385-391.
23. Settle EC Jr. Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry. 1998;59(suppl 16):25-30. Discussion in: J Clin Psychiatry. 1998;59(suppl 16):40-42.
24. Settle EC Jr. Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry. 1998;59(suppl 16):25-30. Discussion in: J Clin Psychiatry. 1998;59(suppl 16):40-42.
25. Spigset O, Hedenmalm K. Hyponatremia and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by psychotropic drugs. Drug Saf. 1995;12(3):209-225.
26. DePaulo JR Jr. Lithium. Psychiatr Clin North Am. 1984;7(3):587-599.
27. Desai AK, Grossberg GT. Herbals and botanicals in geriatric psychiatry. Am J Geriatr Psychiatry. 2003; 11(5):498-506.
28. Lawlor PG. The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal. Cancer. 2002;94(6):1836-1853.
29. Marcantonio ER, Juarez G, Goldman L, et al. The relationship of postoperative delirium with psychoactive medications. JAMA. 1994;272(19):1518- 1522.
30. Bortz JJ. Neuropsychiatric and memory issues in epilepsy. Mayo Clin Proc. 2003;78(6):781-787.
31. Desai AK. Use of psychopharmacologic agents in the elderly. Clin Geriatr Med. 2003;19(4):697-719.
32. Sirven JI. Antiepileptic drug therapy for adults: when to initiate and how to choose. Mayo Clin Proc. 2002;77(12):1367-1375.
33. White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology. 2003;61(9):1218-1221.
34. Browning CH. Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. Int J Psychiatry Med. 1996;26(1):25-34.
35. Weinrich S, Sarna L. Delirium in the older person with cancer. Cancer. 1994;74(suppl 7):2079-2091.
36. Eisendrath SJ, Sweeney MA. Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations. Am J Psychiatry. 1987;144(4):506-507.
37. Ganzini L, Walsh JR, Millar SB. Drug-induced depression in the aged. What can be done? Drugs Aging. 1993;3(2):147-158.
38. Patten SB, Love EJ. Drug-induced depression. Psychother Psychosom. 1997;66(2):63-73.
39. Van Gool AR, Kruit WH, Engels FK, Stoter G, Bannink M, Eggermont AM. Neuropsychiatric side effects of interferon-alfa therapy Pharm World Sci. 2003;25(1):11-20.
40. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry. 2000;157(6):867-876.
41. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol. 1994;21(2):241-243.
42. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961-966.
43. Ling MH, Perry PJ, Tsuang MT. Side effects of corticosteroid therapy. Psychiatric aspects. Arch Gen Psychiatry. 1981;38(4):471-477.
44. Grossberg GT, Desai AK. Late-life psychosis. In: Mellow A, ed. Geriatric Psychiatry: Review of Psychiatry. Vol 22. Washington, DC: American Psychiatric Association; 2003:75-110.
45. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf. 2003;26(9):643-659.
46. Patten SB, Love EJ. Neuropsychiatric adverse drug reactions: passive reports to Health and Welfare Canada's adverse drug reaction database (1965-present). Int J Psychiatry Med. 1994;24(1):45-62.
47. Haddad P, Lejoyeux M, Young A. Antidepressant discontinuation reactions. BMJ. 1998;316(7138):1105-1106.
48. Blenkinsopp A, Bradley C. Patients, society, and the increase in self medication. BMJ. 1996;312(7031):629-632.
49. van Eijk ME, Bahri P, Dekker G, et al. Use of prevalence and incidence measures to describe age-related prescribing of antidepressants with and without anticholinergic effects. J Clin Epidemiol. 2000;53(6):645-651.
50. Baillargeon L, Landreville P, Verreault R, Beauchemin JP, Gregoire JP, Morin CM. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial. CMAJ. 2003; 169(10):1015-1020.
51. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;281(11):991-999.
52. Sussman D, GareIy A. Treatment of overactive bladder with once-daily, extended release tolterodine or oxybutinin: the antimuscarininc clinical effectiveness trial [ACET]. Curr Med Res Opin. 2002;18(4):177-184.
53. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(11 suppl):S1-S5.
54. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002;113(9):746-750.